US pharma group to pay €90.5mn for 8% in deal that will boost joint Lyme disease programme
Pfizer buys stake in French vaccine maker Valneva
Related Posts
Hims & Hers’ Strategic Expansion into Canada: Leveraging ZAVA Acquisition and Generic Semaglutide for Market Disruption
Hims & Hers Health's planned 2026 Canadian expansion represents a pivotal strategic shift, combining its recent acquisition of European digital health platform ZAVA with the anticipated launch of...
Merck’s $10 Billion Verona Pharma Acquisition: Strategic Masterstroke in the COPD Therapeutics Revolution
The pharmaceutical industry witnessed a landmark transaction on July 9, 2025, as Merck & Co. announced its definitive agreement to acquire Verona Pharma for approximately $10 billion, securing...
Torrent Pharma’s $1.4B JB Pharma Acquisition: KKR Exit Catalyzes CDMO Power Play
In a landmark transaction reshaping India's pharmaceutical landscape, Torrent Pharmaceuticals announced the acquisition of KKR's 46.39% controlling stake in JB Chemicals & Pharmaceuticals for...
Danone’s Strategic Acquisition of The Akkermansia Company: Accelerating Leadership in Next-Generation Biotics
Danone has significantly advanced its gut health research capabilities through the acquisition of The Akkermansia Company, a pioneer in next-generation probiotics and postbiotics. This strategic...